Purple Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . Purple Biotech
PPBT Stock  USD 2.19  0.35  13.78%   
Purple Biotech financial statements provide useful quarterly and yearly information to potential Purple Biotech investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Purple Biotech financial statements helps investors assess Purple Biotech's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Purple Biotech's valuation are summarized below:
Gross Profit
-120 K
Market Capitalization
4.1 M
Enterprise Value Revenue
33.0832
Earnings Share
81
There are currently one hundred twenty trending fundamental ratios for Purple Biotech that can be evaluated and compared over time across competitors. All traders should check out Purple Biotech's recent fundamentals against the performance from 2010 to 2024 and make sure the trends continue to evolve in the right direction. Enterprise Value is likely to gain to about 11 M in 2024, whereas Market Cap is likely to drop slightly above 16.9 M in 2024.

Purple Biotech Total Revenue

0.0

Check Purple Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Purple Biotech's main balance sheet or income statement drivers, such as Depreciation And Amortization of 208.9 K, Interest Expense of 2.3 M or Selling General Administrative of 4.6 M, as well as many indicators such as Price To Sales Ratio of 84.89, Dividend Yield of 0.088 or PTB Ratio of 0.49. Purple financial statements analysis is a perfect complement when working with Purple Biotech Valuation or Volatility modules.
  
Check out the analysis of Purple Biotech Correlation against competitors.
For more information on how to buy Purple Stock please use our How to Invest in Purple Biotech guide.

Purple Biotech Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets32.4 M44.3 M23.8 M
Slightly volatile
Other Current Liabilities2.2 M3.5 M1.8 M
Slightly volatile
Total Current Liabilities3.7 M7.2 M3 M
Slightly volatile
Accounts Payable3.7 M3.5 M1.1 M
Slightly volatile
Cash8.4 M14.5 M6.2 M
Slightly volatile
Cash And Short Term Investments19.6 M15.4 M14.4 M
Slightly volatile
Net Receivables545.1 K575 K429.7 K
Slightly volatile
Common Stock Shares Outstanding232.4 M221.3 M39.2 M
Slightly volatile
Liabilities And Stockholders Equity32.4 M44.3 M23.8 M
Slightly volatile
Non Current Liabilities Total3 M2.8 M762.9 K
Slightly volatile
Other Current Assets357.2 K376 K976.8 K
Very volatile
Other Stockholder Equity72.8 M133.2 M53.9 M
Slightly volatile
Total Liabilities10.5 M10 M4 M
Slightly volatile
Total Current Assets20.9 M15.8 M15.4 M
Slightly volatile
Accumulated Other Comprehensive Income40.4 M38.5 M8.1 M
Slightly volatile
Property Plant And Equipment Net409.3 K470 K253.2 K
Slightly volatile
Non Current Assets Total29.9 M28.5 M9.7 M
Slightly volatile
Property Plant And Equipment Gross409.3 K470 K253.2 K
Slightly volatile
Other Liabilities124 K130.5 K330.7 K
Very volatile
Net Tangible Assets24 M30.2 M19.1 M
Slightly volatile
Short Term Investments876.9 K923 K10.8 M
Pretty Stable
Property Plant Equipment451.2 K784.3 K280.2 K
Slightly volatile
Current Deferred Revenue580.8 K1.1 M483.4 K
Slightly volatile
Net Invested Capital39.9 M34.2 M23 M
Slightly volatile
Net Working Capital8.2 M8.6 M12.3 M
Slightly volatile
Short Term Debt363.9 K188 K1 M
Slightly volatile
Intangible Assets26.6 K28 K8.2 M
Pretty Stable
Short and Long Term Debt Total437.3 K351 K345.2 K
Slightly volatile
Capital Lease Obligations437.3 K351 K345.2 K
Slightly volatile
Non Currrent Assets Other136.8 K144 K2.3 M
Slightly volatile
Other Assets136.8 K144 K2.3 M
Slightly volatile
Good Will22.4 M25.2 M27.5 M
Slightly volatile

Purple Biotech Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Expense2.3 M2.2 M391.8 K
Slightly volatile
Selling General Administrative4.6 M4.8 M3.6 M
Slightly volatile
Other Operating Expenses12.4 M22.3 M9.3 M
Slightly volatile
Research Development17.9 M17 M6.2 M
Slightly volatile
Interest Income344.4 K474 K245.2 K
Slightly volatile
Minority Interest92.2 K97 K792.5 K
Slightly volatile
Reconciled Depreciation165.5 K197 K83.1 K
Slightly volatile
Cost Of Revenue189.9 K196 K70.2 K
Slightly volatile
Selling And Marketing Expenses308.7 K369.1 K258 K
Slightly volatile

Purple Biotech Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Cash From Financing Activities5.2 M5.4 M8.5 M
Pretty Stable
Stock Based Compensation1.4 M1.9 M1.1 M
Slightly volatile
End Period Cash Flow8.4 M14.5 M6.2 M
Slightly volatile
Begin Period Cash Flow7.6 M15 M5.2 M
Slightly volatile
Depreciation129.2 K197 K79.4 K
Slightly volatile
Other Cashflows From Investing Activities584.4 K556.6 K227.3 K
Slightly volatile
Issuance Of Capital Stock1.5 M1.6 M5.2 M
Very volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio84.89119146
Slightly volatile
Dividend Yield0.0880.10.1117
Slightly volatile
Days Sales Outstanding250210242
Slightly volatile
Stock Based Compensation To Revenue8.2211.0115.1808
Slightly volatile
Capex To Depreciation0.01450.01522.0449
Slightly volatile
EV To Sales55.9935.71106
Slightly volatile
Payables Turnover0.05830.05550.0076
Slightly volatile
Sales General And Administrative To Revenue6.636.9836.8929
Slightly volatile
Research And Ddevelopement To Revenue82.2178.348.0754
Slightly volatile
Capex To Revenue0.01670.01760.0859
Slightly volatile
Cash Per Share0.06620.06962.098
Slightly volatile
Days Payables Outstanding6.2 K6.6 K5.4 M
Slightly volatile
Income Quality0.621.00230.6497
Slightly volatile
Intangibles To Total Assets0.320.6330.4125
Pretty Stable
Current Ratio2.092.1984.6607
Slightly volatile
Receivables Turnover1.081.211.3191
Slightly volatile
Graham Number0.01680.017730.7947
Slightly volatile
Debt To Equity0.30.340.3723
Slightly volatile
Capex Per Share0.00.00.0043
Slightly volatile
Revenue Per Share0.0010.0010.0146
Very volatile
Interest Debt Per Share8.0E-48.0E-40.2539
Slightly volatile
Debt To Assets0.140.150.1642
Slightly volatile
Days Of Payables Outstanding6.2 K6.6 K5.4 M
Slightly volatile
Total Debt To Capitalization0.220.250.2701
Slightly volatile
Debt Equity Ratio0.30.340.3723
Slightly volatile
Quick Ratio2.092.1985.1254
Slightly volatile
Net Income Per E B T9.0E-40.0010.8333
Slightly volatile
Cash Ratio2.972.01712.2095
Pretty Stable
Days Of Sales Outstanding250210242
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.81.00020.9905
Slightly volatile
Fixed Asset Turnover0.460.484.1669
Pretty Stable
Debt Ratio0.140.150.1642
Slightly volatile
Price Sales Ratio84.89119146
Slightly volatile
Asset Turnover0.00480.00510.0149
Very volatile

Purple Biotech Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap16.9 M20.2 M17.6 M
Slightly volatile

Purple Fundamental Market Drivers

Cash And Short Term Investments15.4 M

Purple Upcoming Events

14th of February 2024
Upcoming Quarterly Report
View
21st of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
14th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Purple Biotech Financial Statements

Purple Biotech shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Purple Biotech investors may analyze each financial statement separately, they are all interrelated. The changes in Purple Biotech's assets and liabilities, for example, are also reflected in the revenues and expenses on on Purple Biotech's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue1.1 M580.8 K
Cost Of Revenue196 K189.9 K
Stock Based Compensation To Revenue 11.01  8.22 
Sales General And Administrative To Revenue 6.98  6.63 
Research And Ddevelopement To Revenue 78.30  82.21 
Capex To Revenue 0.02  0.02 
Ebit Per Revenue 102.37  107.49 

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Purple Stock Analysis

When running Purple Biotech's price analysis, check to measure Purple Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Purple Biotech is operating at the current time. Most of Purple Biotech's value examination focuses on studying past and present price action to predict the probability of Purple Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Purple Biotech's price. Additionally, you may evaluate how the addition of Purple Biotech to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY